Editor's Choice – Bypass versus Angioplasty for Severe Ischaemia of the Leg (BASIL) Prospective Cohort Study and the Generalisability of the BASIL-2 Randomised Controlled Trial
Author:
Publisher
Elsevier BV
Subject
Cardiology and Cardiovascular Medicine,Surgery
Reference15 articles.
1. Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia;Conte;Eur J Vasc Endovasc Surg,2019
2. Multicentre randomised controlled trial of the clinical and cost-effectiveness of a bypass-surgery-first versus a balloon-angioplasty-first revascularisation strategy for severe limb ischaemia due to infrainguinal disease. The Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial
3. Comparison of clinical outcomes in patients selected for infra-popliteal bypass or plain balloon angioplasty for chronic limb threatening ischemia between 2009 and 2013;Popplewell;Vasc Endovascular Surg,2020
4. Relationship between WIfI stage and quality of life at revascularization in the BEST-CLI trial;Siracuse;J Vasc Surg,2023
5. Procedural and 12-month in-hospital costs of primary infra-popliteal bypass surgery, infrapopliteal best endovascular treatment, and major lower limb amputation for chronic limb threatening ischemia;Popplewell;J Vasc Surg,2022
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Responses to the Main Critiques of the Bypass Versus Angioplasty in Severe Ischemia of the Leg (BASIL)-2 Trial;Annals of Vascular Surgery;2024-10
2. Will We Ever Stop Calling for Larger Trials and Finally Change Research Practice?;European Journal of Vascular and Endovascular Surgery;2024-08
3. Causes, prevention, and management of diabetes-related foot ulcers;The Lancet Diabetes & Endocrinology;2024-07
4. Surgery or Endovascular Therapy for Patients With Chronic Limb-Threatening Ischemia? What do BASIL-2 and BEST-CLI Tell Us;Angiology;2024-02-09
5. BEST-CLI International Collaborative: planning a better future for patients with chronic limb-threatening ischaemia globally;British Journal of Surgery;2024-01-31
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3